Administration of palivizumab: a medical provider's perspective.
Helm
Elizabeth A
EA
Department of Pediatrics, Division of General Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland 21201-1512, USA.
Cummings
Ginny E
GE
Keane
Virginia
V
King
James C
JC
D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000191:economics; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000191:economics; D003362:Cost-Benefit Analysis; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007348:Insurance, Health / Q000191:economics / Q000706:statistics & numerical data; D000069455:Palivizumab; D018357:Respiratory Syncytial Virus Infections / Q000188:drug therapy*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab